Intravenous immunoglobulin for in-vitro fertilization failure

Area of Science:

• Reproductive Endocrinology
• Immunology

Background:

• Unexplained infertility and recurrent implantation failure pose significant challenges in assisted reproductive technologies.
• Identifying effective treatments for patients with a history of failed in-vitro fertilization (IVF) is crucial.

Purpose of the Study:

• To evaluate the efficacy of intravenous immunoglobulin (IVIg) in improving pregnancy rates for women with unexplained IVF failure.
• To determine if IVIg effectiveness varies based on prior IVF cycle performance, specifically oocyte fertilization and embryo yield.

Main Methods:

• A cohort of 29 women with unexplained infertility and previous IVF failures were studied.
• Women were stratified into two groups based on oocyte fertilization rates (> or = 50% vs. < 50%) and embryo yield (>= 3 vs. < 3).
• All participants received a single dose of IVIg (500 mg/kg) before their subsequent embryo transfer.

Main Results:

• A significantly higher pregnancy rate was observed in the group with favorable prior IVF performance (56%) compared to the group with suboptimal performance (8%) after IVIg treatment (P = 0.02).
• Pregnancy occurred in 9 out of 16 women with >= 50% oocyte fertilization and >= 3 embryos per cycle.
• Only 1 out of 13 women with < 50% oocyte fertilization and < 3 embryos per cycle achieved pregnancy.

Conclusions:

• Intravenous immunoglobulin (IVIg) appears beneficial for treating unexplained IVF failure, particularly in women with a history of good oocyte fertilization and embryo production.
• IVIg may be a viable therapeutic option for a specific subset of patients experiencing recurrent IVF failure.